炎症性肠病
炎症
医学
纤维化
疾病
炎症性肠病
胃肠病学
内科学
免疫学
作者
Virginia Solitano,Vipul Jairath,Federica Ungaro,Laurent Peyrin–Biroulet,Silvio Danese
出处
期刊:Med
[Elsevier]
日期:2024-04-01
标识
DOI:10.1016/j.medj.2024.03.010
摘要
Summary
The pivotal role of TL1A in modulating immune pathways crucial for inflammatory bowel disease (IBD) and intestinal fibrosis offers a promising therapeutic target. Phase 2 trials (TUSCANY and ARTEMIS-UC) evaluating an anti-TL1A antibody show progress in expanding IBD therapeutic options. First-in-human data reveal reduced expression of genes associated with extracellular matrix remodeling and fibrosis post-anti-TL1A treatment. Investigational drug TEV-48574, potentially exerting dual antifibrotic and anti-inflammatory effects, is undergoing a phase 2 basket study in both ulcerative colitis (UC) and Crohn disease (CD). Results are eagerly awaited, marking advancements in IBD therapeutics. This critical review comprehensively examines the existing literature, illuminating TL1A and the intricate role of DR3 in IBD, emphasizing the evolving therapeutic landscape and ongoing clinical trials, with potential implications for more effective IBD management.
科研通智能强力驱动
Strongly Powered by AbleSci AI